Clin2
NCT07769983Possibly a fitEnrolling by invitation

HIV vaccine study for people on effective treatment

People Living With HIVAntibody Response

This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old.
  • You have HIV and have been on antiretroviral therapy (ART) for at least 1 year, with your viral load under 50 copies/ml.
  • Your CD4 count is above 250.
  • You have not received an experimental HIV vaccine or anti-HIV antibody before.
  • You are not pregnant and are willing to use effective contraception if needed.
  • You are enrolled in the Swiss HIV Cohort Study (SHCS).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07054931Recruiting· Phase 2
Combination HIV vaccine and antibody therapy study

This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.

London
NCT05983874Enrolling by invitation· Phase 1
Booster HIV vaccine study for those who got the first shots

This study tests two booster doses of an HIV vaccine to see if they are safe and boost the immune system. It is for healthy adults who already received three earlier doses of a related vaccine.

Amsterdam
NCT07675629Not yet recruiting· Phase 2
HIV vaccine safety and immune response study

This study tests a new HIV vaccine in healthy, HIV-negative adults to see if it is safe and creates an immune response. The vaccine uses DNA and a protein to try to teach your body to fight HIV.

Boston, Massachusetts
NCT06205056Recruiting· Phase 1
HIV vaccine safety and immune response test

This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.

Kampala
NCT06484335Recruiting· Phase 1
Testing an HIV vaccine and antibody combo for treatment-free control

This study tests a combination of an HIV vaccine and an antibody infusion to see if your immune system can control HIV without daily pills. You would temporarily stop your HIV medication under close monitoring and restart if needed.

Pathum Wan, Bangkok
NCT07569029Recruiting· Phase 1
HIV vaccine with treatment break to boost immune response

This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.

Birmingham, Alabama

Hear when a new People Living With HIV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.